How to increase the value of randomised trials in COPD research

European Respiratory Journal

Volumn 34, Issue 3, 2009, Pages 552-558

  Puhan, M A ^a,b   Schunemann H J ^c,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c MCMASTER UNIVERSITY   (Canada)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Evidence based medicine; Study design

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; FEASIBILITY STUDY; FORCED EXPIRATORY VOLUME; HUMAN; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL RESEARCH; MORTALITY; PATIENT DECISION MAKING; PHYSICIAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; VALIDITY;

HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 70349095195     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00095408     Document Type: Review

References (31)

1. Puhan MA, Schunemann HJ, Frey M, et al. Value of supplemental interventions to enhance the effectiveness of physical exercise during respiratory rehabilitation in COPD patients. A systematic review. Respir Res 2004; 5: 25. (Pubitemid 41358071)
2. Puhan MA, Schunemann HJ, Frey M, et al. How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction. Thorax 2005; 60: 367-375. (Pubitemid 40685818)
3. Bausch B, Spaar A, Kleijnen J, et al. Quality of randomised trials in COPD research. Eur Respir J 2009; Epub ahead of print: PMID 19574328.
4. Calverley PM, Rennard SI. What have we learned from large drug treatment trials in COPD? Lancet 2007; 370: 774-785.
5. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694. (Pubitemid 32322245)
6. Rothman KJ. Epidemiologic methods in clinical trials. Cancer 1977; 39: Suppl. 4, 1771-1775.
7. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365: 176-186.
8. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005; 365: 82-93.
9. Weiss NS, Koepsell TD, Psaty BM. Generalizability of the results of randomized trials. Arch Intern Med 2008; 168: 133-135.
10. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to clinicians? BMJ 2008; 336: 995-998.
11. Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174: 605-614. (Pubitemid 44330555)
12. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 809-813.
13. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23: 28-33. (Pubitemid 38088492)
14. Ramirez-Venegas A, Sansores RH, Perez-Padilla R, et al. Survival of patients with chronic obstructive pulmonary disease due to biomass smoke and tobacco. Am J Respir Crit Care Med 2006; 173: 393-397. (Pubitemid 43228326)
15. Puhan MA, Mador MJ, Held U, et al. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008; 32: 637-643.
16. Puhan MA, Busching G, Schunemann HJ, et al. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2006; 145: 816-825. (Pubitemid 351650335)
17. Schunemann HJ, Goldstein R, Mador MJ, et al. A randomised trial to evaluate the self-administered standardised chronic respiratory questionnaire. Eur Respir J 2005; 25: 31-40. (Pubitemid 40207728)
18. Puhan MA, Guyatt GH, Goldstein R, et al. Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir Med 2007; 101: 308-316.
19. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204. (Pubitemid 17009877)
20. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. (Pubitemid 38807371)
21. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789. (Pubitemid 46294610)
22. Schunemann HJ, Griffith L, Jaeschke R, et al. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol 2003; 56: 1170-1176. (Pubitemid 37532803)
23. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
24. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 1439-1450.
25. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380-390.
26. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
27. Wilt TJ, Niewoehner D, MacDonald R, et al. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med 2007; 147: 639-653. (Pubitemid 351664485)
28. Lundh A, Gotzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol 2008; 8: 22. (Pubitemid 351678111)
29. Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003; 326: 1171-1173.
30. Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet 2005; 365: 1348-1353. (Pubitemid 40501299)
31. Akl EA, Grant BJ, Guyatt GH, et al. A decision aid for COPD patients considering inhaled steroid therapy: development and before and after pilot testing. BMC Med Inform Decis Mak 2007; 7: 12.